BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• FDA

  U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

  U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY ® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia.

  August 14, 2023

   · 

  14 min read
• Pharm Country

  Koneksa Launches Academic Collaboration Program for Parkinson’s Disease

  Koneksa announced the first collaboration in the Koneksa Academic Partnership Program for Parkinson’s Disease to incorporate its Neuroscience Toolkit into research programs.

  August 14, 2023

   · 

  3 min read
• Business

  Jaguar Health Reports Second Quarter 2023 Financial Results

  Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated second-quarter 2023 financial results and provided Company updates.

  August 14, 2023

   · 

  13 min read
• Business

  Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  Vaccinex, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.

  August 14, 2023

   · 

  15 min read
• Business

  Allogene Therapeutics Appoints Earl Douglas as General Counsel

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that Earl Douglas has been appointed as General Counsel.

  August 14, 2023

   · 

  5 min read
• Business

  Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update

  Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”) today released its financial results for the quarter ended June 30, 2023 and provided a business update.

  August 14, 2023

   · 

  4 min read
• Business

  ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

  ContraFect Corporation announces business updates and financial results for the second quarter ended June 30, 2023.

  August 14, 2023

   · 

  12 min read
• Drug Development

  SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis

  SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results from their SFA-002 Phase 1b cohort 1 clinical trial.

  August 14, 2023

   · 

  3 min read
• Business

  IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla

  IMUNON, Inc. announces the addition of Sachet A. Shukla, Ph.D. to the company’s scientific advisory board (SAB).

  August 14, 2023

   · 

  5 min read
• Drug Development

  Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

  Ketabon, a joint venture between HMNC Brain Health and Develco Pharma, announced today top-line results from its Phase 2 KET01-02 Ketabon study with lead asset KET01.

  August 14, 2023

   · 

  5 min read